Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
The observed association between elevated Lp(a) levels and statin use is primarily driven by confounding by indication, reflecting the patients' higher baseline risk profile rather than a direct biological effect of the medication.
Abstract
The persistence of coronary events in statin-treated patients highlights residual risk mechanisms beyond low-density lipoprotein cholesterol (LDL-C), with lipoprotein(a) [Lp(a)] playing a pivotal role. Treatment with statins has been suggested to be associated with an elevation in plasma Lp(a) levels, though the clinical significance remains uncertain.
This study analyzes Lp(a) levels and their relationship with prior statin therapy, as well as their association with a diagnosis of atherosclerotic cardiovascular disease (ASCVD) prior to admission in patients hospitalized for acute coronary syndrome (ACS).
This observational study included 729 patients admitted for ACS with available Lp(a) measurements. Clinical variables, lipid profile, prior statin therapy, and adherence assessed by the 8-item Morisky Medication Adherence Scale were recorded. The association between prior statin therapy and log-transformed Lp(a) levels was evaluated using multivariable linear regression adjusted for confounding factors. Additionally, propensity score matching (1:1 nearest neighbor, caliper 0.2) was performed as a sensitivity analysis, yielding 117 matched pairs. Sample size was estimated a priori to ensure 80% power (α=0.05) to detect a small effect size (Cohen’s d = 0.20). Based on an estimated standard deviation of 1.33, a minimum of 722 participants was required; thus, the final cohort of 729 patients (361 on statins and 368 statin-naive) provided adequate statistical power.
Prior statin therapy was present in 49.5% of patients. These subjects exhibited lower LDL-C and apoB, but higher Lp(a) levels (77 [26–181] vs. 56 [26–133] nmol/L; p = 0.009) (figure). However, this association lost significance after multivariable adjustment (B = 0.025; 95% CI −0.204 to 0.255; p = 0.829) and propensity score adjustment (p = 0.686). Neither statin intensity [84 (29–187) vs. 71 (31–174) nmol/L; p = 0.644] nor treatment adherence [78 (29–192) vs. 79 (31–178) nmol/L; p = 0.749] influenced Lp(a) levels. Female sex was the only independent predictor of Lp(a) levels (table). Conversely, elevated Lp(a) was independently associated with prior ASCVD (OR 1.638; 95% CI 1.115–2.405; p = 0.012), indicating that higher Lp(a) levels are more prevalent in patients with recurrent cardiovascular events.
In ACS patients, Lp(a) remains a marker of residual cardiovascular risk independent of statin therapy. The observed association between elevated Lp(a) levels and statin use is primarily driven by confounding by indication, reflecting the patients' higher baseline risk profile rather than a direct biological effect of the medication.FigureTable
In ACS patients, the predictive value of lipid biomarkers for disease severity is fundamentally modified by prior LLT, and in patients on prior LLT, Lp(a) emerged as a strong independent predictor of severe ASCVD, whereas lower apoB levels were paradoxically associated with higher disease burden, likely reflecting more...
A. M. Hernandez, F. Santiago, J. M. Andreu Cayuelas et al.· European Heart Journal· 0 citations
Lipoprotein(a) [Lp(a)] is an established genetically determined cardiovascular risk factor; however, comprehensive real-world data on its distribution and clinical significance in patients hospitalized with acute coronary syndromes (ACS) remain limited. We aimed to characterize Lp(a) concentrations in a contempor...
Michał Miszczak, Beata Mokrauz, P. Piwowarczyk et al.· BMC Cardiovascular Disorders· 0 citations
A clear dose–response relationship was observed, with progressively higher odds of multivessel CAD across increasing Lp(a) quartiles, underscoring the contribution of Lp(a) to residual atherosclerotic risk beyond traditional cardiometabolic factors.
P. Theofilis, P. Vlachakis, A. Papanikolaou et al.· European Heart Journal· 0 citations
Although the expanding therapeutic armamentarium allows for increased substantial LDL-c reductions, this has not translated into a corresponding improvement in target attainment and the underlying reasons are complex and multifactorial.
Thomas de Saint Nicolas, Hubert Dromas, Gilles Lemesle· Annales de cardiologie et d'...· 0 citations
Background:
Elevated lipoprotein(a) [Lp(a)] is an independent causal cardiovascular risk factor affecting approximately 20% of the population. Whether this enhanced risk persists in individuals on treatment with low LDL-C levels remains a subject of controversy. We hypothesized that achieving LDL <70 mg/dL would att...
Scott D. Eisenberg, B. Evenhuis, J. Medina-Inojosa et al.· Circulation· 0 citations
Aspirin may be considered for primary prevention in selected patients with diabetes mellitus (DM). Lipoprotein(a) [Lp(a)] is an independent cardiovascular risk factor linked to myocardial infarction and stroke and may promote thrombogenicity. Whether the association between aspirin use and cardiovascular outcomes...
M. Rossi, E. Tartaglia, A. Askarinejad et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.